Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 5/20 | 0.44 |
| ▸ | GLA | P06280 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | ALPL | P05186 | 1/20 | 0.35 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | ABL1 | P00519 | 3/20 | 0.34 |
| ▸ | SRC | P12931 | 2/20 | 0.34 |
| ▸ | SYK | P43405 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | CDK1 | P06493 | 1/20 | 0.34 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25508045 | 1.00 | XDH (0.44) | XDHGLAGAACYP1A2ALPL | |
| SCHEMBL888365 | 0.78 | CYP1A2 (0.41) | XDHGLAGAACYP1A2MAPK1 | |
| SCHEMBL25507489 | 0.78 | XDH (0.44) | XDHGLAGAACYP1A2ALPL | |
| SCHEMBL20504460 | 0.70 | XDH (0.47) | XDHGLAGAACYP1A2ALPL | |
| SCHEMBL25508042 | 0.70 | XDH (0.49) | XDHGLAGAACYP1A2ALPL | |
| SCHEMBL8985899 | 0.70 | ALDH1A1 (0.67) | XDHGLAGAAALPLMAPK1 | |
| SCHEMBL30418792 | 0.70 | XDH (0.49) | XDHGLAGAACYP1A2ALPL | |
| SCHEMBL4822348 | 0.69 | XDH (0.43) | XDHGLAGAACYP1A2ALPL | |
| SCHEMBL4827008 | 0.69 | XDH (0.43) | XDHGLAGAACYP1A2ALPL | |
| SCHEMBL3283667 | 0.68 | NSD2 (0.61) | XDHGLAGAAHRH4ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250136607-A1 | PAD4 INHIBITORS AND USE THEREOF | REGOR PHARMACEUTICALS, INC. | 2025-05-01 | — | — | US | disclosed |
| EP-4433477-A1 | PAD4 INHIBITORS AND USE THEREOF | Regor Pharmaceuticals, Inc. (US) | 2024-09-25 | — | — | EP | disclosed |
| CN-118679162-A | PAD4 inhibitors and uses thereof | 锐格药业公司 | 2024-09-20 | — | — | CN | disclosed |
| WO-2023083365-A1 | PAD4 INHIBITORS AND USE THEREOF | QILU REGOR THERAPEUTICS INC. (CN) | 2023-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250136607-A1 | PAD4 INHIBITORS AND USE THEREOF | PADI4, PADI6, PADI2 | XDH 90/4885GLA 3211/4885GAA 804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.